# Observational Study Protocol: LIVER-R

> **NCT06252753** · — · RECRUITING · sponsor: **AstraZeneca** · enrollment: 4490 (estimated)

## Conditions studied

- Hepatobiliary Cancers

## Interventions

- **OTHER:** Durvalumab-based combination therapies in observational study setting
- **OTHER:** Durvalumab-based combination therapies in observational study setting

## Key facts

- **NCT ID:** NCT06252753
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2023-03-16
- **Primary completion:** 2030-12-30
- **Final completion:** 2030-12-30
- **Target enrollment:** 4490 (ESTIMATED)
- **Last updated:** 2025-12-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06252753

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06252753, "Observational Study Protocol: LIVER-R". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06252753. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*